The critical role of macrophage migration inhibitory factor in insulin activity

Cytokine

Volumn 69, Issue 1, 2014, Pages 39-46

  Vujicic, Milica ^a   Senerovic, Lidija ^a   Nikolic, Ivana ^a   Saksida, Tamara ^a   Stosic Grujicic, Stanislava ^a   Stojanovic, Ivana ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Insulin; Insulin activity; Insulin synthesis; Macrophage migration inhibitory factor

Indexed keywords

INSULIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN KINASE B; ANTIBODY; EPITOPE; ISOMERASE; MIF PROTEIN, MOUSE; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GLUCOSE TRANSPORT; HORMONE ACTION; INSULIN DEGRADATION; INSULIN RESPONSE; INSULIN SYNTHESIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN FUNCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL LINE; DRUG EFFECTS; GENETICS; GLUCOSE INTOLERANCE; HEPG2 CELL LINE; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; LIVER CELL; METABOLISM; PHOSPHORYLATION; PROTEIN FOLDING;

ANIMALS; ANTIBODIES; CELL LINE; EPITOPES; GLUCOSE INTOLERANCE; HEP G2 CELLS; HEPATOCYTES; HUMANS; INSULIN; INSULIN-SECRETING CELLS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN FOLDING; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS;

EID: 84901770846     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.05.013     Document Type: Article

References (28)

1. Bloom B.R., Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966, 153:80-82.
2. Calandra T., Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3:791-800.
3. Baugh J.A., Donnelly S.C. Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol 2003, 179:15-23.
4. Calandra T., Bernhagen J., Mitchell R.A., Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179:1895-1902.
5. Rosengren E., Aman P., Thelin S., Hansson C., Ahlfors S., Björk P., et al. The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett 1997, 417:85-88.
6. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377:68-71.
7. Cherepkova O.A., Lyutova E.M., Eronina T.B., Gurvits B.Y. Chaperone-like activity of macrophage migration inhibitory factor. Int J Biochem Cell Biol 2006, 38:43-55.
8. Stosic-Grujicic S., Stojanovic I., Nicoletti F. MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev 2009, 8:244-249.
9. Kleemann R., Bucala R. Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. Mediators Inflamm 2010, 2010:610479.
10. Bojunga J., Kusterer K., Bacher M., Kurek R., Usadel K.H., Renneberg H. Macrophage migration inhibitory factor and development of type-1 diabetes in non-obese diabetic mice. Cytokine 2003, 21:179-186.
11. Dandona P., Aljada A., Ghanim H., Mohanty P., Tripathy C., Hofmeyer D., et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004, 89:5043-5047.
12. Herder C., Kolb H., Koenig W., Haastert B., Müller-Scholze S., Rathmann W., et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care 2006, 29:368-371.
13. Cvetkovic I., Al-Abed Y., Miljkovic D., Maksimovic-Ivanic D., Roth J., Bacher M., et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 2005, 146:2942-2951.
14. Stosic-Grujicic S., Stojanovic I., Maksimovic-Ivanic D., Momcilovic M., Popadic D., Harhaji L., et al. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol 2008, 215:665-675.
15. Stojanovic I., Saksida T., Nikolic I., Nicoletti F., Stosic-Grujicic S. Macrophage migration inhibitory factor deficiency protects pancreatic islets from cytokine-induced apoptosis in vitro. Clin Exp Immunol 2012, 169:156-163.
16. Saksida T., Stosic-Grujicic S., Timotijevic G., Sandler S., Stojanovic I. Macrophage migration inhibitory factor deficiency protects pancreatic islets from palmitic acid-induced apoptosis. Immunol Cell Biol 2012, 90:688-698.
17. Waeber G., Calandra T., Roduit R., Haefliger J.A., Bonny C., Thompson N., et al. Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1997, 94:4782-4787.
18. Serre-Beinier V., Toso C., Morel P., Gonelle-Gispert C., Veyrat-Durebex C., Rohner-Jeanrenaud F., et al. Macrophage migration inhibitory factor deficiency leads to age-dependent impairment of glucose homeostasis in mice. J Endocrinol 2010, 206:297-306.
19. Saksida T., Stošić-Grujičić S., Stojanović I. The role of macrophage migration inhibitory factor in obesity-associated type 2 diabetes in mice. Arch Biol Sci Belgrade 2013, 65:499-505.
20. Fingerle-Rowson G., Petrenko O., Metz C.N., Forsthuber T.G., Mitchell R., Huss R., et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci USA 2003, 100:9354-9359.
21. Rydgren T., Sandler S. Efficacy of 1400W, a novel inhibitor of inducible nitric oxide synthase, in preventing interleukin-1beta-induced suppression of pancreatic islet function in vitro and multiple low-dose streptozotocin-induced diabetes in vivo. Eur J Endocrinol 2002, 147:543-551.
22. Al-Abed Y., Dabideen D., Aljabari B., Valster A., Messmer D., Ochani M., et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 2005, 280:36541-36544.
23. Hegde B., Vadnal P., Sanghavi J., Korde V., Kulkarni-Almeida A.A., Dagia N.M. Vitamin E is a MIF Inhibitor. Biochem Biophys Res Commun 2012, 418:384-389.
24. Andrusier N., Nussinov R., Wolfson H.J. FireDock: fast interaction refinement in molecular docking. Proteins 2007, 69:139-159.
25. Mashiach E., Schneidman-Duhovny D., Andrusier N., Nussinov R., Wolfson H.J. FireDock: a web server for fast interaction refinement in molecular docking. Nucleic Acids Res 2008, 36:W229-W232.
26. Benigni F., Atsumi T., Calandra T., Metz C., Echtenacher B., Peng T., et al. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest 2000, 106:1291-1300.
27. Nikolic I., Vujicic M., Saksida T., Berki T., Stosic-Grujicic S., Stojanovic I. The role of endogenous glucocorticoids in glucose metabolism and immune status of MIF-deficient mice. Eur J Pharmacol 2013, 714:498-506.
28. Kim M.K., Kim H.S., Lee I.K., Park K.G. Endoplasmic reticulum stress and insulin biosynthesis: a review. Exp Diabetes Res 2012, 2012:509437.